Skip to nav Skip to content

Clinical Trial Search

319 Clinical Trials Found

Clinical Trial 20494

A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Disease Site: Melanoma, skin
PI: Tarhini, Ahmad

Clinical Trial 20751

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
Disease Site: Non-Hodgkin's Lymphoma
PI: Chavez, Julio

Clinical Trial 21193

Disease Site: Brain and Nervous System, Brain metastasis
PI: Yu, Hsiang-Hsuan (Michael)

Clinical Trial 21459

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Disease Site: Colon
PI: Imanirad, Iman

Clinical Trial 20894

Acalabrutinib for Chronic Graft-versus-Host Disease
Disease Site: Unknown Sites
PI: Pidala, Joseph

Clinical Trial 21366

Administration of HIV-specific T Cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue -Auto-RESIST
Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
PI: Lazaryan, Aleksandr

Clinical Trial 20163

EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non©\Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature©\driven Analysis
Disease Site: Lung, Non small cell lung cancer
PI: Gray, Jhanelle

Clinical Trial 21894

Phase 1 Clinical Trial of lntravesical Adoptive Cell Therapy {ACT) with Tumor Infiltrating Lymphocytes (TIL) for Patients with BCG Exposed High Grade Non-Muscle Invasive Bladder Cancer {NMIBC)
Disease Site: Urinary Bladder
PI: Poch, Michael

Clinical Trial 21673

A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety ofHER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-Based Therapy (FLAMINGO-01)
Disease Site: Breast
PI: Soyano Muller, Aixa

Clinical Trial 20571

Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination with Pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T-cell Immunotherapy
Disease Site: Lymphoma, Non-Hodgkin's Lymphoma
PI: Locke, Frederick

Clinical Trial 21518

A Phase 1/1b Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation Positive Solid Tumors
Disease Site: Any Site
PI: Kim, Richard

Clinical Trial 21850

Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors
Disease Site: Lung
PI: Pellini, Bruna